Last update July 16, 2022



Safe substance and/or breastfeeding is the best option.

It is a calcitonin gene-related peptide receptor antagonist. It is ndicated for the treatment of migraine. Oral administration once daily.

Its pharmacokinetic data (high percentage of protein binding, large volume of distribution and moderately high molecular weight) explain the negligible passage into breast milk observed. (Baker 2022)

Expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed)



Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Rimegepant in other languages or writings:

  • C28H28F2N6O3 (Molecular formula)
  • N02CD06 (ATC Code/s)


Rimegepant belongs to this group or family:


Main tradenames from several countries containing Rimegepant in its composition:


Variable Value Unit
Oral Bioavail. 64 %
Molecular weight 535 daltons
Protein Binding 96 %
VD 1.7 l/Kg
pKa 10.7 -
Tmax 1.5 hours
11 hours
M/P ratio 0.2 -
Theoretical Dose 0.005 mg/Kg/d
Relative Dose 0.51 %


  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on April 10, 2024 Full text (link to original source)
  3. Baker TE, Croop R, Kamen L, Price P, Stock DA, Ivans A, Bhardwaj R, Anderson MS, Madonia J, Stringfellow J, Bertz R, Coric V, Hale TW. Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women. Breastfeed Med. 2022 Mar;17(3):277-282. Consulted on April 5, 2022 Abstract Full text (link to original source)
  4. FDA. Rimegepant (Nurtec) Drug Summary. 2020 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM